Group 1 - GSK and Ionis Pharmaceuticals have reported positive results from two key Phase III clinical trials for bepirovirsen, a drug aimed at achieving functional cure for chronic hepatitis B (HBV) [1][2] - The global chronic HBV infection population is approximately 254 million, with around 75 million in China, highlighting a significant unmet medical need for effective treatments [1] - Functional cure does not equate to complete virus eradication but significantly reduces the risks of liver cancer and cirrhosis, aligning with current drug development trends in chronic HBV [1] Group 2 - Bepirovirsen, an antisense oligonucleotide (ASO) therapy, aims to identify and destroy the genetic components of the HBV, potentially allowing patients' immune systems to regain control over the infection [2] - Domestic companies are also advancing innovative drug development for functional cure of HBV, with Guangsheng Tang's GST-HG141 and Dongyangguang Pharmaceutical's GLS4 both in Phase III trials [3] - Other companies like Zhimeng Pharmaceutical and Haobo Pharmaceutical are developing HBV core inhibitors and novel ASO drugs, respectively, indicating a growing pipeline for HBV treatment [4] Group 3 - Experts in the field have noted that while functional cure for HBV may not achieve the same results as the complete eradication seen with hepatitis C, the advancements in research are significant for future drug development [5]

Group 1 - The company, Fujian Guangshengtang Pharmaceutical Co., Ltd., is participating in a national major science and technology project aimed at exploring new treatment options for chronic hepatitis B, which has received official approval from the National Health Commission [2][3]. - The project, titled "Research on New Combined Treatment Plans for Clinical Cure of Chronic Hepatitis B," is led by Southern Medical University and will run from December 2025 to November 2028, focusing on improving clinical cure rates and developing guidelines for hepatitis B treatment in China [3][4]. - The company is involved in two specific research topics within the project, which include studies on the use of antisense oligonucleotides and multi-target sequential therapies to enhance clinical cure rates for hepatitis B [4]. Group 2 - The project is significant as it aligns with national health strategies, including the "Healthy China 2030" plan, and aims to strengthen the country's capacity to respond to emerging infectious diseases [4][5]. - Data from Polaris Observatory indicates that there are approximately 79.74 million HBV carriers in China, with chronic hepatitis B patients numbering between 20 million and 30 million, highlighting the public health challenge posed by this disease [5]. - The national action plan for hepatitis B prevention and treatment aims for an 80% diagnosis rate and an 80% treatment rate for chronic hepatitis B patients by 2030, marking a shift towards a focus on "cure" [6]. Group 3 - As a participant in the national project, the company will collaborate closely with leading research teams and clinical centers, which may enhance its competitive edge in the hepatitis B treatment sector [7]. - The company's innovative drugs, GST-HG141 and GST-HG131, have been recognized as breakthrough treatment candidates and are currently undergoing clinical trials, with GST-HG141 having successfully enrolled its first participant in a Phase III trial [7]. - The sequential combination therapy plan, part of the company's "Hepatitis B Summit Plan," is positioned as an exploratory research scheme within the national project, which could facilitate the clinical development and commercialization of its innovative drugs [7].

智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司(简 称"广生中霖")参与申报的新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合治 疗新方案研究"项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广生中霖 作为课题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的研究工作，且在研乙肝创新药 GST-HG131、GST-HG141及联合用药将作为项目课题研究用药。 ...

广生堂（300436）(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司(简称"广生 中霖")参与申报的新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合治疗新方 案研究"项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广生中霖作为课 题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的研究工作，且在研乙肝创新药GST- HG131、GST-HG141及联合用药将作为项目课题研究用药。 ...

Core Viewpoint - The announcement by Guangshengtang regarding its innovative hepatitis B drugs aligns with national policies aimed at achieving "clinical cure" for hepatitis B, receiving substantial support from the government [1][2]. Group 1: Project Overview - Guangshengtang's subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., has been included in a national major science and technology project focused on the clinical cure of chronic hepatitis B [1][2]. - The project, led by Southern Medical University, aims to explore and establish a clinically applicable hepatitis B cure and improve cure rates by 2028 [2]. Group 2: Market Demand and Public Health Significance - As of 2022, there are approximately 79.74 million HBV infected individuals in China, with chronic hepatitis B patients numbering between 20 to 30 million, highlighting a significant unmet clinical need [3]. - The national action plan for hepatitis virus prevention and control sets ambitious targets for diagnosis and treatment rates by 2030, emphasizing the urgency for innovative treatment solutions [3]. Group 3: Drug Development and Clinical Trials - The two innovative drugs, GST-HG131 and GST-HG141, are central to Guangshengtang's strategy and have shown strong competitive potential internationally [4][5]. - GST-HG131 is the first oral hepatitis B surface antigen inhibitor to complete Phase II clinical trials, demonstrating significant reductions in HBsAg levels [4]. - GST-HG141, a novel core protein regulator, has shown promising results in reducing HBV pgRNA levels, indicating potential for addressing the challenges of treatment discontinuation [5]. Group 4: Strategic Implications for Guangshengtang - Participation in the national project will provide Guangshengtang with expert guidance and collaboration opportunities, reinforcing its leading position in hepatitis B treatment [6]. - Successful outcomes from the project could influence industry standards and contribute to the development of clinical guidelines for chronic hepatitis B treatment in China [6].

格隆汇1月5日丨广生堂(300436.SZ)公布，公司创新药控股子公司福建广生中霖生物科技有限公司（简 称"广生中霖"）参与申报的新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合 治疗新方案研究"项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广生中 霖作为课题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的研究工作，且在研乙肝创新 药GST-HG131、GST-HG141及联合用药将作为项目课题研究用药。 ...

Core Viewpoint - Guangshengtang (300436.SZ) announced that its subsidiary, Guangsheng Zhonglin, has received a project approval notification for a national science and technology major project focused on the prevention and control of emerging infectious diseases, specifically for the research of new combined treatment plans for chronic hepatitis B clinical cure [1] Group 1 - The project aims to explore new combined treatment plans to improve the clinical cure rate of hepatitis B [1] - Guangsheng Zhonglin is responsible for research tasks one and three, utilizing the innovative hepatitis B drugs GST-HG131, GST-HG141, and combination therapies as research medications [1] - This project affirms the company's technological innovation capabilities and research and development strength in the field of hepatitis B treatment, highlighting its core competitiveness in related areas [1]

证券代码：300436 证券简称：广生堂 公告编号：2026001 项目编号：2025ZD01905900 福建广生堂药业股份有限公司 关于创新药子公司参与新发突发与重大传染病防控 国家科技重大专项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、基本情况 福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公司福建 广生中霖生物科技有限公司（以下简称"广生中霖"）参与申报的新发突发与重 大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合治疗新方案研究" 项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广 生中霖作为课题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的 研究工作，且在研乙肝创新药 GST-HG131、GST-HG141 及联合用药将作为项目课 题研究用药。 （一）项目基本情况 项目名称：慢性乙型肝炎临床治愈联合治疗新方案研究 项目牵头承担单位：南方医科大学南方医院 项目执行年限：2025 年 12 月-2028 年 11 月 项目目标方向，旨在探索获得可推广应用的乙肝临床治愈方案并提高临床治 愈率 ...

广生堂公告称，其创新药控股子公司广生中霖参与申报的"慢性乙型肝炎临床治愈联合治疗新方案研 究"国家科技重大专项已立项。该项目执行期为2025年12月至2028年11月，广生中霖参与课题一和课题 三，负责研究工作，在研乙肝创新药GST - HG131、GST - HG141及联合用药为研究用药。这是对公司 技术和研发实力的肯定，若成果达预期，将积极影响公司乙肝创新药发展，但项目实施存在进度和结果 不及预期等风险。 ...

2026年A股首个交易日，市场一片热闹景象。 一方面，上证指数再度站上4000点，日线迎来罕见的12连阳。另一方面，权重股搭台，个股普涨，热点全面开花。 权重股方面，保险板块大涨；此外，贵州茅台（600519）、宁德时代（300750）、中芯国际等龙头股均上涨。板块方面，脑机接口、医药、半导体、消费 电子等板块大涨。 截至上午收盘，上证指数上涨1.07%，报4011.45点；深证成指上涨1.87%，创业板指上涨2.15%。 | 新华保险 融 601336 | 74.95 | 7.53% | 1563 Z | | --- | --- | --- | --- | | 中国太保 | 44.49 | 6.16% | 3045亿 | | 融 601601 | | | | | 行业龙头3 | | | | | 中国平安 ■ 601318 | 72.20 | 5.56% | 7697亿 | | 行业龙头2 | | | | | 中国人寿 融 601628 | 47.85 | 5.16% | 9964 Z | | 行业龙头1 | | | | | 中国人保 融 601319 | 9.38 | 4.80% | 3330亿 | 202 ...